John Bowers, DO
Radiation Oncology · Houston, TXNPI 1902218001
Payments from drug & device makers
Across 65 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$281
- AstraZeneca$136
- Johnson & Johnson$72
- Sobi, Inc$71
- Daiichi Sankyo Inc.$69
- Exelixis Inc.$61
- plus $605 from 21 others
What the payments were for
- Food & beverage$1,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $281 |
| AstraZeneca | 8 | $136 |
| Johnson & Johnson | 3 | $72 |
| Sobi, Inc | 3 | $71 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Exelixis Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Genentech USA, Inc. | 2 | $46 |
| Incyte Corporation | 2 | $39 |
| Karyopharm Therapeutics Inc. | 2 | $37 |
| Merck | 2 | $36 |
| Astellas Pharma US Inc | 2 | $36 |
| Siemens Medical Solutions USA, Inc. | 1 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Seagen Inc. | 2 | $33 |
| Genmab U.S., Inc. | 2 | $32 |
| GSK | 2 | $30 |
| Geron Corporation | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Sanofi | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| ADC Therapeutics America, Inc. | 1 | $15 |
| Beone Medicines USA, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Pfizer | 1 | $14 |
How this compares
$1,294 in reported general payments places this provider in the 60th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 116 | $1,550 |
| Oxybutynin Chloride ErOxybutynin Chloride | 42 | $725 |
| Dexamethasone | 40 | $454 |
| SsdSilver Sulfadiazine | 12 | $414 |
| Fluconazole | 15 | $313 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $206 |
| Gabapentin | 13 | $164 |
| Ondansetron Hcl | 14 | $155 |
| Tramadol Hcl | 19 | $116 |
| Lorazepam | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Houston
- Daniel GomezHouston$8.7M
- Chad TangHouston$7.7M
- James WelshHouston$5.1M
- Caroline ChungHouston$3.7M
- Karen HoffmanHouston$2.6M
- Clifton FullerHouston$1.6M
- Steven LinHouston$1.5M
- Chenyang WangHouston$1.4M
- Joe ChangHouston$1.2M
- Lilie LinHouston$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.